60 Degrees Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton have jointly reported beneficial ownership of 191,571 shares, representing 5.45% of 60 Degrees Pharmaceuticals, Inc. common stock.
NASDAQ
Knight Therapeutics Inc. has disclosed beneficial ownership of 658,629 shares, representing 19.85% of the outstanding common stock of 60 Degrees Pharmaceuticals, Inc.
NASDAQ
CVI Investments, Inc. and Heights Capital Management, Inc. have filed a Schedule 13G, reporting beneficial ownership of 7.0% of 60 Degrees Pharmaceuticals, Inc. common stock.
NASDAQ
Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, reported beneficial ownership of 263,158 shares, representing 9.1% of 60 Degrees Pharmaceuticals, Inc. common stock.
NASDAQ
Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have filed an amended Schedule 13G, reporting a combined beneficial ownership of 4.14% in 60 DEGREES PHARMACEUTICALS, INC.
NASDAQ
Intracoastal Capital LLC and its principals, Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in 60 Degrees Pharmaceuticals, Inc. common stock.
NASDAQ
CVI Investments and Heights Capital Management report a 9.9% beneficial ownership in 60 Degrees Pharmaceuticals, primarily through warrants.
NASDAQ
SCHEDULE: CVI Investments and Heights Capital Management Disclose 9.9% Stake in 60 Degrees Pharmaceuticals
CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a 9.9% beneficial ownership stake in 60 Degrees Pharmaceuticals, Inc., comprising 328,102 common shares.
NASDAQ
A group comprising Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC has reported beneficial ownership of 9.99% of 60 Degrees Pharmaceuticals, Inc.'s common stock.
NASDAQ
Orca Capital AG has filed an amended Schedule 13G, reporting a 4.9% beneficial ownership stake in 60 Degrees Pharmaceuticals, Inc., holding 166,229 shares of common stock.
NASDAQ
Orca Capital AG has reported a 9.9% beneficial ownership stake in 60 Degrees Pharmaceuticals, Inc., holding 320,000 shares of common stock.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in 60 Degrees Pharmaceuticals, Inc. as of March 31, 2025.
NASDAQ
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly reported a 9.99% beneficial ownership stake in 60 Degrees Pharmaceuticals, Inc. through the holding of warrants.
NASDAQ
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in 60 Degrees Pharmaceuticals
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 476,866 shares, representing 9.99% of 60 Degrees Pharmaceuticals, Inc.'s common stock as of December 31, 2024.
NASDAQ
SCHEDULE 13G: Intracoastal Capital Group Discloses 4.99% Passive Stake in 60 Degrees Pharmaceuticals
A group comprising Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC has disclosed a 4.99% beneficial ownership stake in 60 Degrees Pharmaceuticals, Inc., primarily through warrants with blocker provisions.
NASDAQ
SCHEDULE 13G: Intracoastal Capital Group Discloses 4.99% Passive Stake in 60 Degrees Pharmaceuticals
A group comprising Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC has disclosed a passive beneficial ownership of 4.99% in 60 Degrees Pharmaceuticals, Inc. common stock.